ANL

Adlai Nortye (ANL)

About Adlai Nortye (ANL)

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Details

Daily high

$9.55

Daily low

$8.88

Price at open

$9.24

52 Week High

$17.25

52 Week Low

$0.88

Market cap

315.9M

Dividend yield

0.00%

Volume

221,389

Avg. volume

202,776

P/E ratio

-9.14

Adlai Nortye News